DOI QR코드

DOI QR Code

Comprehensive Analysis of Temozolomide Treatment for Patients with Glioma

  • Yang, Wen-Bing (Department of Radiology, Renmin Hospital of Wuhan University) ;
  • Xing, Bian-Zhi (Department of Radiology, Renmin Hospital of Wuhan University) ;
  • Liang, Hua (Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University)
  • Published : 2014.10.23

Abstract

Background: This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma. Methods: Clinical studies evaluating the efficacy and safety of temozolomide based regimens for patients with glioma were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: In temozolomide based regimens, 5 clinical studies including 152 patients with advanced glioma were considered eligible for inclusion. Four clinical studies included temozolomide. Systematic analysis suggested that, in all patients, pooled CR was 21% (32/152), and PR was 21% (32/152). Grade 3/4 toxicity included neutropenia, thrombocytopenia, and anemia. No grade 3 or 4 renal or liver toxicity was observed. No treatment related death occurred with temozolomide based treatment. Conclusion: This systematic analysis suggests that temozolomide based regimens are associated with mild response rate and acceptable toxicity for treatment of glioma patients.

Keywords

Glioma;temozolomide chemotherapy;efficacy;toxicity

References

  1. Brandes AA, Tosoni A, Cavallo G, et al (2006) .Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer, 95, 1155-60. https://doi.org/10.1038/sj.bjc.6603376
  2. Athanassiou H, Synodinou M, Maragoudakis E, et al (2005). Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol, 23, 2372-7. https://doi.org/10.1200/JCO.2005.00.331
  3. Chen C, Xu T, Lu Y, et al (2013). The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol, 20, 223-30. https://doi.org/10.1111/j.1468-1331.2012.03778.x
  4. Cheng HB, Xie C, Zhang RY, et al (2013). Xeroderma pigmentosum complementation group f polymorphisms influence risk of glioma. Asian Pac J Cancer Prev, 14, 4083-7. https://doi.org/10.7314/APJCP.2013.14.7.4083
  5. Gaviani P, Salmaggi A, Silvani A (2008). Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. J Neurooncol, 104, 617-18.
  6. Ge YF, Sun J, Jin CJ, et al (2013). AntagomiR-27a targets FOXO3a in glioblastoma and suppresses U87 cell growth in vitro and in vivo. Asian Pac J Cancer Prev, 14, 963-8. https://doi.org/10.7314/APJCP.2013.14.2.963
  7. Luo KQ, Mu SQ, Wu ZX, et al (2013). Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev, 14, 449-52. https://doi.org/10.7314/APJCP.2013.14.1.449
  8. Jiang J, Quan XF, Zhang L, et al (2013). The XRCC3 Thr241Met polymorphism influences glioma risk - a meta-analysis. Asian Pac J Cancer Prev, 14, 3169-73. https://doi.org/10.7314/APJCP.2013.14.5.3169
  9. Khasraw M, Bell D, Wheeler H (2009). Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci, 16, 854-5. https://doi.org/10.1016/j.jocn.2008.09.005
  10. Liang HJ, Yan YL, Liu ZM, et al (2013). Association of XRCC3 Thr241Met polymorphisms and gliomas risk: evidence from a meta-analysis. Asian Pac J Cancer Prev, 14, 4243-7. https://doi.org/10.7314/APJCP.2013.14.7.4243
  11. National Cancer Institute. CTCAE v3.0. Available at http://www.cancer.gov (accessed on 9 August 2006).
  12. Ohgaki H, Kleihues P (2009). Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci, 100, 2235-41. https://doi.org/10.1111/j.1349-7006.2009.01308.x
  13. Qian ZZ, Wang HQ, Liu XM, et al (2009). [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma]. Zhonghua Yi Xue Za Zhi, 89, 2059-62. Chinese.
  14. Quinn JA1, Jiang SX, Reardon DA, et al (2009). Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol, 95, 393-00. https://doi.org/10.1007/s11060-009-9937-x
  15. Reardon DA, Herndon JE, II, Peters K, et al (2011). Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol, 107, 213-21.
  16. Santoni M, Paccapelo A, Burattini L, Onofri A, Cascinu S (2012). Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. Anticancer Res, 32, 1099-01.
  17. Strik HM, Marosi C, Kaina B, et al (2012). Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep, 12, 286-93. https://doi.org/10.1007/s11910-012-0262-y
  18. Shen D, Yang QY, Chen ZP (2012). [Advances in the chemotherapy of malignant gliomas with temozolomide]. Chin J Neurooncol, 4, 271-6. Chinese.
  19. Shen D, Yang QY, Chen ZP. Advances in the chemotherapy of malignant gliomas with temozolomide. Chin J Neurooncol, 4, 271-6. Chinese.
  20. Silvani A, Lamperti E, Gaviani P, et al (2008). Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol, 87, 143-51. https://doi.org/10.1007/s11060-007-9427-y
  21. Stupp R, Dietrich PY, Kraljevic S, et al (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20, 1375-82. https://doi.org/10.1200/JCO.20.5.1375
  22. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. J Clin Oncol, 25, 4127-36. https://doi.org/10.1200/JCO.2007.11.8554
  23. Stupp R, Hegi ME, Mason WP, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol, 10, 459-66. https://doi.org/10.1016/S1470-2045(09)70025-7
  24. Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. https://doi.org/10.1056/NEJMoa043330
  25. Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. https://doi.org/10.1056/NEJMoa043330
  26. Tosoni A1, Franceschi E, Ermani M, et al (2008). Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol, 89, 179-85. https://doi.org/10.1007/s11060-008-9600-y
  27. Wang YX, Fan K, Tao DB, et al (2013). Association between genetic polymorphism of xrcc1 gene and risk of Glioma in? Chinese population. Asian Pac J Cancer Prev, 14, 5957-60. https://doi.org/10.7314/APJCP.2013.14.10.5957
  28. Verhoeff JJ, Lavini C, van Linde ME, et al (2010). Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol, 21, 1723-7. https://doi.org/10.1093/annonc/mdp591
  29. Vredenburgh JJ, Desjardins A, Herndon JE, II, et al (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 25, 4722-29 https://doi.org/10.1200/JCO.2007.12.2440
  30. Walker MD, Green SB, Byar DP, et al (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 303, 1323-9. https://doi.org/10.1056/NEJM198012043032303
  31. Yan YI, Tang WY, Deng ZX, et al (2007). [Efficacy of temozolomide in treatment of recurrent glioma]. Cancer Res Prev Treat, 17, 1359-64. Chinese.
  32. Yang P, Wang Y, Peng X, et al (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 113, 259-66. https://doi.org/10.1007/s11060-013-1103-9
  33. Yu CY, Liang GB, Du P, et al (2013). Lgr4 promotes glioma cell proliferation through activation of Wnt signaling. Asian Pac J Cancer Prev, 14, 4907-11. https://doi.org/10.7314/APJCP.2013.14.8.4907
  34. Zhou LF, Wang RZ, Bao SD, et al (2012). Chinese guideline for diagnosis and treatment on central nervous system tumors. Zhonghua Yi Xue Za Zhi, 92, 2309-13.
  35. Zhu Y, Zhuang JX, Wang Q, et al (2013). Inhibitory effect of benzyl isothiocyanate on proliferation in vitro of human glioma cells. Asian Pac J Cancer Prev, 14, 2607-10. https://doi.org/10.7314/APJCP.2013.14.4.2607
  36. Zustovich F1, Lombardi G, Della Puppa A, et al (2009). A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res, 29, 4275-9.
  37. Zwinkels H, Roon K, Jeurissen FJ, et al (2009). Management of temozolomide toxicity by nurse practitioners in neurooncology. Oncol Nurs Forum, 36, 225-31. https://doi.org/10.1188/09.ONF.225-231

Cited by

  1. Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature vol.91, pp.4, 2017, https://doi.org/10.1007/s00204-016-1810-z